NXC736 not checked

NEXTGEN Bioscience

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Alopecia Areata
Main trialPhase 2
“The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).”In the company’s words, NCT06104839 on ClinicalTrials.gov

Other drugs for Alopecia Areata

All 16 drugs for Alopecia Areata

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 31 Oct 2026 Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata
Phase 1Completed 1 Nov 2022 A First-in-Human Study to Assess Single and Multiple Doses of NXC736 in Healthy Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow NXC736

Following is part of Solo: you see every change to NXC736 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in